Diabetes is a growing global epidemic. Each year, millions of diabetics go blind or suffer from unnecessary vision loss as a result of diabetic retinopathy, a common complication of diabetes. While diabetic retinopathy has become the leading cause of blindness, 95% of cases are preventable and treatable if detected early enough through an annual retinal exam. However, only half of patients with diabetes are being screened for diabetic retinopathy. For many, the disease goes undetected until it’s too late as patients are unaware they even have the condition. For payers and health systems, the cost of treating diabetic retinopathy is significantly higher than any investments in prevention and early detection of the disease. For patients, the impact of vision impairment represents fundamental diminution of the quality of life. For over a decade, Retina Labs has been on the leading edge of teleophthalmology innovation. Its cloud-based iVision teleophthalmology platform offers an integrated solution that combines advanced ocular imaging, clinical interpretation and reporting tools with electronic referrals. iVision offers a comprehensive, workflow-based solution for diabetic retinopathy screening. iVision provides all the capabilities necessary to manage a teleretinal screening program including image acquisition, clinical diagnosis and reporting. iVision allows primary care providers, health systems and payers to improve screening compliance rates, drive quality outcome measures and to lower costs associated with the treatment of diabetic retinopathy.